{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:50:15Z","timestamp":1783486215338,"version":"3.55.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.lungcan.2021.08.009","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T01:38:15Z","timestamp":1630287495000},"page":"34-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC"],"prefix":"10.1016","volume":"161","author":[{"given":"Nanruoyi","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A","family":"Velez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bachrach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaklin","family":"Gukasyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene M.","family":"Fares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackson P.","family":"Lind-Lebuffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wisdom O.","family":"Akingbemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debory Y.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige M.","family":"Brodrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawal M.","family":"Yessuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Rettinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Rochigneux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward B.","family":"Garon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Lisberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.lungcan.2021.08.009_b0005","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.lungcan.2021.08.009_b0010","first-page":"2018","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"Lung Cancer"},{"issue":"17","key":"10.1016\/j.lungcan.2021.08.009_b0015","first-page":"1627","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non\u2013Small-Cell","volume":"373","author":"Borghaei","year":"2015","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2021.08.009_b0020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.lungcan.2021.08.009_b0025","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.lungcan.2021.08.009_b0030","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2021.08.009_b0035","unstructured":"N. National Comprehensive Cancer, Management of Immunotherapy-Related Toxicities Version 3.2021, 2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf. (accessed 7\/6\/2021 2021)."},{"issue":"3","key":"10.1016\/j.lungcan.2021.08.009_b0040","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer - ScienceDirect","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann. Oncol."},{"issue":"03","key":"10.1016\/j.lungcan.2021.08.009_b0045","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors","volume":"51","author":"de Filette","year":"2019","journal-title":"Horm. Metab. Res."},{"issue":"1","key":"10.1016\/j.lungcan.2021.08.009_b0050","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1634\/theoncologist.2013-0237","article-title":"Hypothyroidism after a cancer diagnosis: etiology, diagnosis, complications, and management","volume":"19","author":"Carter","year":"2014","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.lungcan.2021.08.009_b0055","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1634\/theoncologist.2017-0375","article-title":"Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune-Checkpoint Inhibitors for Cancer Treatment","volume":"23","author":"Patel","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.lungcan.2021.08.009_b0060","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-Related Adverse Events Associated with Anti-PD-1\/PD-L1 Treatment for Malignancies: A Meta-Analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.lungcan.2021.08.009_b0065","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"25","key":"10.1016\/j.lungcan.2021.08.009_b0070","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2021.08.009_b0075","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13044-019-0063-3","article-title":"Hypothyroidism in the older population","volume":"12","author":"Leng","year":"2019","journal-title":"Thyroid Res"},{"issue":"9","key":"10.1016\/j.lungcan.2021.08.009_b0080","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/M15-0483","article-title":"Screening for thyroid dysfunction: U.S. Preventive Services Task Force recommendation statement","volume":"162","author":"LeFevre","year":"2015","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2021.08.009_b0085","first-page":"99","article-title":"Thyroid Disorders in the Oncology Patient","volume":"6","author":"Hartmann","year":"2015","journal-title":"J Adv Pract Oncol"},{"issue":"6","key":"10.1016\/j.lungcan.2021.08.009_b0090","doi-asserted-by":"crossref","first-page":"e0156925","DOI":"10.1371\/journal.pone.0156925","article-title":"Disease-Specific as Well as Generic Quality of Life Is Widely Impacted in Autoimmune Hypothyroidism and Improves during the First Six Months of Levothyroxine Therapy","volume":"11","author":"Winther","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2021.08.009_b0095","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6066.CIR-17-0063","article-title":"Treatment Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center","author":"Lisberg","year":"2018","journal-title":"Cancer Immunol. Res."},{"issue":"10","key":"10.1016\/j.lungcan.2021.08.009_b0100","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid"},{"issue":"12","key":"10.1016\/j.lungcan.2021.08.009_b0105","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1089\/thy.2014.0028","article-title":"Guidelines for the treatment of hypothyroidism: prepared by the American thyroid association task force on thyroid hormone replacement","volume":"24","author":"Jonklaas","year":"2014","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.lungcan.2021.08.009_b0110","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000490384","article-title":"2018 European Thyroid Association Guideline for the Management of Graves\u2019 Hyperthyroidism","volume":"7","author":"Kahaly","year":"2018","journal-title":"Eur. Thyroid J."},{"issue":"1","key":"10.1016\/j.lungcan.2021.08.009_b0115","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s40425-019-0645-6","article-title":"Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance","volume":"7","author":"Couey","year":"2019","journal-title":"J. Immuno Ther. Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2021.08.009_b0120","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40618-017-0772-1","article-title":"Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution","volume":"41","author":"Guaraldi","year":"2018","journal-title":"J. Endocrinol. Invest."},{"issue":"Suppl 7","key":"10.1016\/j.lungcan.2021.08.009_b0125","article-title":"Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy","volume":"58","author":"Abdel-Wahab","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.lungcan.2021.08.009_b0130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejca.2020.02.010","article-title":"The 2016\u20132019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study","volume":"130","author":"Michot","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2021.08.009_b0135","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/ITT.S141577","article-title":"Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events","volume":"6","author":"Davies","year":"2017","journal-title":"Immunotargets Ther"},{"key":"10.1016\/j.lungcan.2021.08.009_b0140","series-title":"Robbins and Cotran pathologic basis of disease","article-title":"The Endocrine System","author":"Kumar","year":"2015"},{"key":"10.1016\/j.lungcan.2021.08.009_b0145","series-title":"Harrison's Principles of Internal Medicine, 19e","article-title":"Disorders of the Thyroid Gland","author":"Jameson","year":"2014"},{"issue":"10027","key":"10.1016\/j.lungcan.2021.08.009_b0150","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.lungcan.2021.08.009_b0155","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"Supplement_7","key":"10.1016\/j.lungcan.2021.08.009_b0160","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kez308","article-title":"Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors","volume":"58","author":"Weinmann","year":"2019","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.lungcan.2021.08.009_b0165","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1158\/1078-0432.CCR-13-2648","article-title":"CTLA4 blockade broadens the peripheral T-cell receptor repertoire","volume":"20","author":"Robert","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.lungcan.2021.08.009_b0170","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1158\/0008-5472.CAN-16-2324","article-title":"Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire","volume":"77","author":"Oh","year":"2017","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.lungcan.2021.08.009_b0175","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13081944","article-title":"Graves' Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review)","volume":"13","author":"Peiffert","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lungcan.2021.08.009_b0180","doi-asserted-by":"crossref","DOI":"10.1177\/2042018819896182","article-title":"Immunotherapy-induced endocrinopathies: assessment, management and monitoring","volume":"10","author":"Nogueira","year":"2019","journal-title":"Ther. Adv. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.lungcan.2021.08.009_b0185","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr. Relat. Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221005109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221005109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:51:32Z","timestamp":1759236692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500221005109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":37,"alternative-id":["S0169500221005109"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.08.009","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}